Singapore, Nov. 19 -- Pfizer Inc. has entered into an exclusive licensing agreement with China-based Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics. Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialise three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programmes that are focused on treating autoimmune diseases.

Pfizer also receives rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive right...